Unifying model of TGFB signaling in breast epithelium

Unifying model of TGFβ signaling in breast epithelium. Implications for cancer treatment using TGFβ pathway antagonists. The model assumes the existence of a primitive multipotent stem cell population that is ER-negative, PR-negative, CD44+, CD24lo, ESA+, KRT5+, TGFbR2+ and possibly express mesenchymal markers. When these cells divide, they give rise either to phenotypically identical daughter stem cells or to precursors of differentiated progeny (luminal, basal, or myoepithelial). Luminal cells are epithelioid (ESA+, KRT8/18+, CDH1+), express ER and PR, are CD44-, CD24+, and the TGFBR2 gene is transcriptionally silent (TGFBR2-). The basal and myoepithelial progeny express basal cytokeratins (KRT5/6/14+) or myoepithelial markers (αSMA, p63), lack ESA (ESA-), and appear to be enriched for CD44+, CD24lo cells. Whether these cells do or do not continue to express TGFBR2 is unclear. One of the fundamental determinants of the proportions of these different subpopulations in normal or cancer tissue is the ratio of stem cell divisions that give rise to daughter stem cells versus differentiated progeny []. We propose that exposure to TGFβ leads to enrichment of the cell population with multipotent CD44+, CD24lo clonogenic/tumor initiating cells that express mesenchymal markers (EMT) [], while treatment with a TGFβ receptor kinase inhibitor leads to enrichment with CD44-, CD24+, TGFBR2- nonclonogenic differentiated luminal cells []. Thus, we would like to propose the idea that TGFβ signaling is a key determinant of the fate of stem cell progeny, and responsible for maintenance of the stem cell pool in the normal mammary gland. Moreover, this model suggests the hypothesis that the constitutive activation of TGFβ signaling associated with invasive and metastatic breast cancer might contribute to steadily enriching the cancer stem cell pool, thereby indirectly enhancing the potential for metastasis and poor patient survival. In this context, it is noteworthy that EMT of normal as well as malignant human mammary epithelial cells appears to be tightly associated with the stem cell state []. Superimposed on to these population dynamics at the tissue level is the role of systemic estrogens and progestins in regulating TGFβ signaling (see section “Extensive cross-talk between estrogen- and TGFβ signaling pathways”). The ER/PR-positive luminal cells respond to estrogen by producing growth factors and lowering TGFβ production. These conditions would favor the commitment of stem cell daughter cells to become more differentiated progenitor cells. Moreover, because the TGFBR2 gene is transcriptionally silenced in these luminal daughter cells, this would further favor their clonal expansion. Conversely, anti-estrogens induce TGFβ production, which, even if it inhibits the rate of stem cell proliferation, would favor their self-renewal over commitment to differentiation. Once cancer stem cells break through the barrier of TGFβ-mediated growth arrest, the presence of active TGFβ would select for continued expansion of the cancer stem cell pool, and, consequently, metastasis. This model predicts that treatment of basal-like cancers with TGFβ antagonists may have anti-tumor effects by converting the putative stem cell population into a luminal, non-proliferating (and, perhaps, non-metastatic), phenotype (mesenchymal-to-epithelial transition, MET). Conversely, these agents might antagonize the therapeutic effects of anti-estrogens in estrogen-dependent luminal cancers. However, once these cells become estrogen-independent because they escape from TGFβ-mediated growth arrest, our model provides a rationale for including TGFβ pathway antagonists in the treatment program. Each of these predictions is testable in model systems as well as in clinical trials
Unifying model of TGFB signaling in breast epithelium

Publication

Transforming growth factor-β signaling: emerging stem cell target in metastatic breast cancer?. () Antoinette R. Tan, et al. Breast Cancer Res Treat. ;115(3):453-495. Figure: F2.

Gene mentions


Organism Group Word Match Source NCBI Symbol NCBI ID
Homo sapiens Primates CD44 CD44 ncbigene_symbol CD44 960
Homo sapiens Primates CD24 CD24 ncbigene_symbol CD24 100133941
Homo sapiens Primates TGFBR2 TGFBR2 ncbigene_symbol TGFBR2 7048
Homo sapiens Primates ESA ESA ncbigene_synonym FLOT2 2319
Homo sapiens Primates ESA ESA ncbigene_synonym EPCAM 4072
Homo sapiens Primates ESA ESA ncbigene_synonym PON1 5444
Homo sapiens Primates ALDHI ALDHI ncbigene_synonym ALDH2 217
Homo sapiens Primates CDH2 CDH2 ncbigene_symbol CDH2 1000
Homo sapiens Primates VIM VIM ncbigene_symbol VIM 7431
Homo sapiens Primates CTGF CTGF ncbigene_synonym CCN2 1490
Homo sapiens Primates SPARC SPARC ncbigene_symbol SPARC 6678
Homo sapiens Primates EMT EMT ncbigene_synonym ITK 3702
Homo sapiens Primates EMT EMT ncbigene_synonym SLC22A3 6581
Homo sapiens Primates CAVI CAVI ncbigene_synonym CA6 765
Homo sapiens Primates CAV2 CAV2 ncbigene_symbol CAV2 858
Homo sapiens Primates TGFA TGFA ncbigene_symbol TGFA 7039
Homo sapiens Primates IGF-1 IGF1 ncbigene_symbol IGF1 3479

Chemical mentions

Word Match MeSH Name ChEBI
Estradiol Estradiol mesh:D004958 17beta-estradiol chebi:16469
estrogens estrogen mesh:D004967 Estrogens chebi:50114
Progestin progestin mesh:D011372 Progestins chebi:59826

Disease mentions

Word Match MeSH Name DOID